Description
Dapaforce (Dapoxetine) 90 mg
Dapaforce is presented as a dapoxetine 90 mg tablet product. Dapoxetine is a short-acting selective serotonin reuptake inhibitor (SSRI) used for the management of premature ejaculation in adult men in jurisdictions where it has been authorised. The exact trade name and strength should always be checked against the local regulatory label, because authorised product information for dapoxetine is not the same in every country.
Active Ingredient and Medicine Class
The verified active ingredient is dapoxetine. It belongs to the SSRI class. Unlike antidepressant SSRIs that are taken continuously, dapoxetine was developed for rapid absorption and short duration of action, which makes it suitable for on-demand use in approved treatment settings.
Established Medical Uses
The established medical use of dapoxetine is the treatment of premature ejaculation in adult men. Authorised product information for the original reference medicine describes use in men aged 18 to 64 years. It is not indicated for general sexual performance enhancement, erectile dysfunction, or other sexual concerns unless a clinician has specifically determined an approved use in the relevant country.
How It Works
Dapoxetine increases serotonin signalling by inhibiting serotonin reuptake in the nervous system. Serotonin is involved in the control of ejaculation, and raising its activity can delay ejaculation in some men. Because dapoxetine is absorbed quickly and leaves the body relatively quickly, it was developed as a short-acting SSRI for targeted use rather than long-term daily therapy.
Important Safety Information
Important contraindications and precautions are described in official product information for dapoxetine products. It should not be used with monoamine oxidase inhibitors, thioridazine, other serotonergic medicines that can raise the risk of serotonin toxicity, or potent CYP3A4 inhibitors such as certain azole antifungals, HIV protease inhibitors, and some antibiotics. Grapefruit juice is also listed in product information as a potent CYP3A4 inhibitor to avoid around treatment.
Product information also states that dapoxetine should not be used in people with moderate or severe liver impairment. Caution is needed in people with a history of fainting, low blood pressure, dizziness on standing, epilepsy, bleeding or clotting problems, significant psychiatric illness, or other sexual dysfunction such as erectile dysfunction. Alcohol may worsen dizziness, sleepiness, and fainting-related risk.
Possible Side Effects
The most commonly reported adverse effects include nausea, dizziness, headache, diarrhoea, somnolence, insomnia, and sometimes fainting or feeling light-headed. Some people also report fatigue, abdominal discomfort, dry mouth, or flushing. Less common but clinically important reactions can include serotonin syndrome, marked drops in blood pressure, mood changes, and bleeding-related problems, especially when combined with other medicines that affect serotonin or clotting.
Scientific Evidence
Human clinical studies and meta-analyses have generally found that dapoxetine can increase intravaginal ejaculatory latency time and improve patient-reported control, satisfaction, and distress compared with placebo. The benefit is usually described as modest to moderate rather than curative. Reviews also note that adverse effects are more frequent than with placebo, but serious events were uncommon in the clinical trial populations studied. Evidence supports its role as a targeted pharmacological option for premature ejaculation, while long-term real-world experience remains more limited than for older medicines.
Medical Information Notice
This page is an educational summary based on authoritative sources available at the time of review. It does not replace the official patient leaflet, country-specific prescribing information, or individual assessment by a qualified healthcare professional.
Medical Sources
- European Medicines Agency (EMA). Priligy referral page and product-information documents for dapoxetine. View official EMA referral information
- European Medicines Agency (EMA). Priligy summary of product characteristics / package leaflet materials. View official product information PDF
- Salonia A et al. Efficacy and safety of dapoxetine in treatment of premature ejaculation: an evidence-based review. International Journal of Clinical Practice, 2016. View scientific article
- Jinhong Li et al. Dapoxetine for premature ejaculation: an updated meta-analysis of randomized controlled trials. Clinical Therapeutics, 2014. View scientific article
